Lv11
38 积分 2022-12-21 加入
Micronuclear collapse from oxidative damage
2小时前
待确认
TRIM21 Ubiquitylates SQSTM1/P62 and Suppresses Protein Sequestration to Regulate Redox Homeostasis
4天前
已完结
Lysosomal enzyme trafficking factor LYSET enables nutritional usage of extracellular proteins
6天前
已完结
Hepatocellular Carcinoma: Pick the Winner-Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent-Based Combinations
6天前
已完结
Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study
14天前
已完结
Targeting Cdc20 for cancer therapy
1个月前
已完结
Portal vein thrombosis: diagnosis, management, and endpoints for future clinical studies
1个月前
已完结
IMbrave150: exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study
1个月前
已完结
Combating KRASG12C Inhibitor Resistance
2个月前
已完结
Adjuvant Alectinib in ALK-Rearranged NSCLC - Here and Now
2个月前
已完结
皖公网安备34019202002308
